search
Back to results

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

Primary Purpose

Drug-resistant

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Dosage 1 of MPCs-derived exosomes
Dosage 2 of MPCs-derived exosomes
No MPCs-derived exosomes
Sponsored by
Ruijin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Drug-resistant focused on measuring human adipose-derived mesenchymal progenitor cell exosomes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- 1.Willingness of study participant to accept this treatment arm, and signed informed consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), was diagnosed within 48 h. The diagnosis must simultaneously comply with the three clinical and radiological criteria described below, which occurred more than 2 d (48 h) after hospitalization, within 7 d after discharge (HAP) or at least 2 d (48 h) after mechanical ventilation (VAP):

  1. The patients had at least one of the following clinical manifestations:

    • New or deteriorating pulmonary symptoms or signs, such as cough, dyspnea, shortness of breath (e.g., respiratory rate higher than 25 beats/min), expectoration or need for mechanical ventilation;
    • Hypoxemia (e.g., when subjects breathe room air at standard atmospheric pressure, the partial pressure of oxygen measured as lower than 60 mmHg by arterial blood gas [ABG], or the ratio of partial pressure of oxygen to fraction of inspired oxygen [PaO2/FiO2] deteriorated);
    • According to the deterioration of oxygenation (ABG or PaO2/FiO2), the support system for the ventilator should be replaced urgently to strengthen oxygenation, or the positive end-expiratory pressure level should be changed;
    • Aspirable respiratory secretions newly appeared;
  2. The patients had at least one of the following signs:

    • Confirmed fever (e.g., body temperature ≥ 38.4℃);
    • Hypothermia (e.g., body temperature ≤ 35℃);
    • Total peripheral white blood cell (WBC) count ≥ 11 × 109/L;
    • Leukopenia, and total WBC ≤ 4 × 109/L;
    • Immature neutrophils (rod-shaped nuclear cells) > 15% was observed on peripheral blood smears;
  3. The chest X-ray of the patients showed new or progressive infiltration, and pneumonia was considered.

4.The pathogenic test of the lower respiratory tract specimens revealed carbapenem-resistant Gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii), which were consistent with the drug resistance spectrum and intermediate or resistant to all carbapenem antibiotics, namely, the minimum inhibitory concentration (MIC) of meropenem or imipenem ≥ 2 μg/ml (2 μg/ml was intermediate and 4 μg/ml was drug-resistant). The MIC of ertapenem ≥ 1 μg/ml, of which 1 μg/ml was intermediate and ≥ 2 μg/ml was drug-resistant.

Exclusion Criteria:

  • 1.Patients with severe allergic constitution or positive skin test result for test products; 2.Confirmed or suspected community acquired pneumonia (CAP); 3.Confirmed or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites; 4.HAP/VAP caused by obstruction, including lung cancer (or other malignant disease that causes lung obstruction) or other known obstructions; 5.Active immunosuppression, it is defined as receiving immunosuppressive drugs or under medical conditions associated with immunodeficiency. Including: 1) HIV (AIDS or CD4 < 200 cells/mm3); 2) received chemotherapy within 6 weeks before randomization; 3) immunosuppressive therapy, including maintenance glucocorticoid therapy (> 40 mg/day Prednisolone equivalent dose); 4) absolute neutrophil count < 500 mg/mm3; additional condition for inclusion: 1) Short-term (within one week) systemic (intravenous or oral) steroid therapy, using steroids for the treatment of skin disorders; 6.History of epilepsy and requirement for continuous anticonvulsant treatment or anticonvulsant treatment received within the last 3 years; 7.Undergoing hemodialysis or peritoneal dialysis; 8.Estimated or actual rate of creatinine clearance < 15 ml/min; 9.It is expected that any of the following drugs will be used during the study: Within 2 weeks before screening, or continuous use of valproic acid or divalproex sodium; 5-selective serotonin reuptake inhibitor, tricyclic antidepressant, 5-HT1 receptor agonist (triptans) or monoamine oxidase inhibitor; monoamine oxidase inhibitor (MAOIs) (or use of MAOIs within 2 weeks before screening) pethidine; buspirone; traditional Chinese medicine or herbal medicine; 10.Lung transplantation; 11.Bone marrow transplantation; 12.History of deep venous thrombosis or pulmonary embolism within the last 3 months; 13.Undergoing ECMO or high-frequency oscillatory ventilation support; 14.The estimated survival time <8 days; 15.HIV, viral hepatitis type B,viral hepatitis type C,or syphilis infection; 16.Period of pregnancy or lactation, or planned pregnancy within 6 months; 17.Incapable of understanding study protocol; 18.Any condition of unsuitable for the study determined by investigators.

Sites / Locations

  • Ruijin Hospital Shanghai Jiao Tong University School of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

MPCs-derived exosomes Dosage 1

MPCs-derived exosomes Dosage 2

No exosomes

Arm Description

low-dose group

high-dose group

No MPCs-derived exosomes

Outcomes

Primary Outcome Measures

Primary Outcome Measures:
1.Clinical cure rate on the 8th d

Secondary Outcome Measures

1.Bacterial clearance rate on the 8th d;
Bacterial clearance rate on the 8th d
2.Mortality on the 28th and 90th d;
Mortality on the 28th and 90th d
3.Recurrence rate after cure within 28 d;
Recurrence rate after cure within 28 d
4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;
Secondary infection rate of other pathogenic bacteria after cure within 28 d
5.Duration of mechanical ventilation within 28 d;
Duration of mechanical ventilation within 28 d
6.Length of ICU stay (d) within 28 d;
Length of ICU stay (d) within 28 d
7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.

Full Information

First Posted
September 3, 2020
Last Updated
September 3, 2020
Sponsor
Ruijin Hospital
Collaborators
Cellular Biomedicine Group Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04544215
Brief Title
A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection
Official Title
A Clinical Study of Allogeneic Human Adipose-derived Mesenchymal Progenitor Cell Exosomes (haMPC-Exos) Nebulizer for the Treatment of Carbapenem-resistant Gram-negative Bacilli-induced Pulmonary Infection
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2020 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
July 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ruijin Hospital
Collaborators
Cellular Biomedicine Group Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Evaluate the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.
Detailed Description
Pulmonary infection is a critical disease threatening human health. With the extensive use of antibiotics, the incidence of clinical drug resistance has been on the rise significantly in recent years. Once drug resistance occurs, we will see a high mortality rate due to scarce therapies and a poor prognosis. It is almost impossible to surmount the severe pulmonary infection caused by drug-resistant bacteria only by upgrading antibiotics. The commonly used supportive therapies clinically, such as glucocorticoids and immunomodulators, also lack forceful medical evidence. Therefore, it is urgent to explore new treatments. Mesenchymal stem/progenitor cell exosomes are nano-sized vesicles secreted by mesenchymal stem/progenitor cells under certain conditions, which contain a lot of proteins, lipids and nucleic acids with tissue repair and immunomodulatory functions. Mesenchymal stem/progenitor cell exosomes are nano-sized vesicles secreted by mesenchymal stem/progenitor cells under certain conditions, which contain a lot of proteins, lipids and nucleic acids with tissue repair and immunomodulatory functions. Currently, it has been confirmed that stem cells can visibly improve the pathological changes of lungs caused by infection, lighten pulmonary edema, reduce protein exudation, mitigate alveolar inflammation, and remove bacteria. Thus, it brings new hope for the treatment of pulmonary infection caused by extensively drug-resistant bacteria. Patients were treated, in the research project, with well-suited noninvasive haMPC-Exos aerosol inhalation, in an attempt to verify the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Drug-resistant
Keywords
human adipose-derived mesenchymal progenitor cell exosomes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MPCs-derived exosomes Dosage 1
Arm Type
Experimental
Arm Description
low-dose group
Arm Title
MPCs-derived exosomes Dosage 2
Arm Type
Experimental
Arm Description
high-dose group
Arm Title
No exosomes
Arm Type
Placebo Comparator
Arm Description
No MPCs-derived exosomes
Intervention Type
Biological
Intervention Name(s)
Dosage 1 of MPCs-derived exosomes
Intervention Description
7 times aerosol inhalation of MPCs-derived exosomes (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
Intervention Type
Biological
Intervention Name(s)
Dosage 2 of MPCs-derived exosomes
Intervention Description
7 times aerosol inhalation of MPCs-derived exosomes (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
Intervention Type
Biological
Intervention Name(s)
No MPCs-derived exosomes
Intervention Description
No aerosol inhalation of MPCs-derived exosomes
Primary Outcome Measure Information:
Title
Primary Outcome Measures:
Description
1.Clinical cure rate on the 8th d
Time Frame
Up to 8 days
Secondary Outcome Measure Information:
Title
1.Bacterial clearance rate on the 8th d;
Description
Bacterial clearance rate on the 8th d
Time Frame
Up to 8 days
Title
2.Mortality on the 28th and 90th d;
Description
Mortality on the 28th and 90th d
Time Frame
Up to 28-90 days
Title
3.Recurrence rate after cure within 28 d;
Description
Recurrence rate after cure within 28 d
Time Frame
Up to 28 days
Title
4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;
Description
Secondary infection rate of other pathogenic bacteria after cure within 28 d
Time Frame
Up to 28 days
Title
5.Duration of mechanical ventilation within 28 d;
Description
Duration of mechanical ventilation within 28 d
Time Frame
Up to 28 days
Title
6.Length of ICU stay (d) within 28 d;
Description
Length of ICU stay (d) within 28 d
Time Frame
Up to 28 days
Title
7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
Description
Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
Time Frame
Up to 28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - 1.Willingness of study participant to accept this treatment arm, and signed informed consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), was diagnosed within 48 h. The diagnosis must simultaneously comply with the three clinical and radiological criteria described below, which occurred more than 2 d (48 h) after hospitalization, within 7 d after discharge (HAP) or at least 2 d (48 h) after mechanical ventilation (VAP): The patients had at least one of the following clinical manifestations: New or deteriorating pulmonary symptoms or signs, such as cough, dyspnea, shortness of breath (e.g., respiratory rate higher than 25 beats/min), expectoration or need for mechanical ventilation; Hypoxemia (e.g., when subjects breathe room air at standard atmospheric pressure, the partial pressure of oxygen measured as lower than 60 mmHg by arterial blood gas [ABG], or the ratio of partial pressure of oxygen to fraction of inspired oxygen [PaO2/FiO2] deteriorated); According to the deterioration of oxygenation (ABG or PaO2/FiO2), the support system for the ventilator should be replaced urgently to strengthen oxygenation, or the positive end-expiratory pressure level should be changed; Aspirable respiratory secretions newly appeared; The patients had at least one of the following signs: Confirmed fever (e.g., body temperature ≥ 38.4℃); Hypothermia (e.g., body temperature ≤ 35℃); Total peripheral white blood cell (WBC) count ≥ 11 × 109/L; Leukopenia, and total WBC ≤ 4 × 109/L; Immature neutrophils (rod-shaped nuclear cells) > 15% was observed on peripheral blood smears; The chest X-ray of the patients showed new or progressive infiltration, and pneumonia was considered. 4.The pathogenic test of the lower respiratory tract specimens revealed carbapenem-resistant Gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii), which were consistent with the drug resistance spectrum and intermediate or resistant to all carbapenem antibiotics, namely, the minimum inhibitory concentration (MIC) of meropenem or imipenem ≥ 2 μg/ml (2 μg/ml was intermediate and 4 μg/ml was drug-resistant). The MIC of ertapenem ≥ 1 μg/ml, of which 1 μg/ml was intermediate and ≥ 2 μg/ml was drug-resistant. Exclusion Criteria: 1.Patients with severe allergic constitution or positive skin test result for test products; 2.Confirmed or suspected community acquired pneumonia (CAP); 3.Confirmed or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites; 4.HAP/VAP caused by obstruction, including lung cancer (or other malignant disease that causes lung obstruction) or other known obstructions; 5.Active immunosuppression, it is defined as receiving immunosuppressive drugs or under medical conditions associated with immunodeficiency. Including: 1) HIV (AIDS or CD4 < 200 cells/mm3); 2) received chemotherapy within 6 weeks before randomization; 3) immunosuppressive therapy, including maintenance glucocorticoid therapy (> 40 mg/day Prednisolone equivalent dose); 4) absolute neutrophil count < 500 mg/mm3; additional condition for inclusion: 1) Short-term (within one week) systemic (intravenous or oral) steroid therapy, using steroids for the treatment of skin disorders; 6.History of epilepsy and requirement for continuous anticonvulsant treatment or anticonvulsant treatment received within the last 3 years; 7.Undergoing hemodialysis or peritoneal dialysis; 8.Estimated or actual rate of creatinine clearance < 15 ml/min; 9.It is expected that any of the following drugs will be used during the study: Within 2 weeks before screening, or continuous use of valproic acid or divalproex sodium; 5-selective serotonin reuptake inhibitor, tricyclic antidepressant, 5-HT1 receptor agonist (triptans) or monoamine oxidase inhibitor; monoamine oxidase inhibitor (MAOIs) (or use of MAOIs within 2 weeks before screening) pethidine; buspirone; traditional Chinese medicine or herbal medicine; 10.Lung transplantation; 11.Bone marrow transplantation; 12.History of deep venous thrombosis or pulmonary embolism within the last 3 months; 13.Undergoing ECMO or high-frequency oscillatory ventilation support; 14.The estimated survival time <8 days; 15.HIV, viral hepatitis type B,viral hepatitis type C,or syphilis infection; 16.Period of pregnancy or lactation, or planned pregnancy within 6 months; 17.Incapable of understanding study protocol; 18.Any condition of unsuitable for the study determined by investigators.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jieming Qu, MD,PhD
Phone
+86-21-64370045
Email
jmqu0906@163.com
Facility Information:
Facility Name
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jieming Qu, MD,PhD
Phone
0086-021-64370045
Email
jmqu0906@163.com
First Name & Middle Initial & Last Name & Degree
Jieming QU, Ph.D., M. D.
First Name & Middle Initial & Last Name & Degree
Yinggang ZHU, Ph.D., M. D.

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
Starting 6 months after publication

Learn more about this trial

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

We'll reach out to this number within 24 hrs